{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:05:47Z","timestamp":1770977147269,"version":"3.50.1"},"reference-count":40,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,3,11]],"date-time":"2011-03-11T00:00:00Z","timestamp":1299801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:p><jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold><\/jats:p><jats:p>\u2022\u2003Rifampicin is known to reduce the exposure of efavirenz. Despite lack of adequate clinical support, most guidelines recommend an increased efavirenz dose in patients treated with both drugs, although some propose an increase only in patients weighing over 50\u2003kg.<\/jats:p><jats:p><jats:bold>WHAT THIS STUDY ADDS<\/jats:bold><\/jats:p><jats:p>\u2022\u2003An example of utilization of<jats:italic>in vitro<\/jats:italic>data to predict<jats:italic>in vivo<\/jats:italic>consequences of metabolic drug\u2013drug interactions, suggesting answers to specific questions difficult to study in patients. Here the efavirenz\u2013rifampicin interaction was simulated with the specific question of whether or not to increase the efavirenz dose based on bodyweight.<\/jats:p><jats:p>\u2022\u2003The results from this simulation suggest that increasing the efavirenz dose may be appropriate only in patients with bodyweights over 50\u2003kg.<\/jats:p><jats:p><jats:bold>AIMS<\/jats:bold>This study aimed to test whether a pharmacokinetic simulation model could extrapolate nonclinical drug data to predict human efavirenz exposure after single and continuous dosing as well as the effects of concomitant rifampicin and further to evaluate the weight\u2010based dosage recommendations used to counteract the rifampicin\u2013efavirenz interaction.<\/jats:p><jats:p><jats:bold>METHODS<\/jats:bold>Efavirenz pharmacokinetics were simulated using a physiologically based pharmacokinetic model implemented in the Simcyp\u2122 population\u2010based simulator. Physicochemical and metabolism data obtained from the literature were used as input for prediction of pharmacokinetic parameters. The model was used to simulate the effects of rifampicin on efavirenz pharmacokinetics in 400 virtual patients, taking into account bodyweight and CYP2B6 phenotype.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold>Apart from the absorption phase, the simulation model predicted efavirenz concentration\u2013time profiles reasonably well, with close agreement with clinical data. The simulated effects of rifampicin co\u2010administration on efavirenz treatment showed only a minor decrease of 16% (95% confidence interval 13\u201319) in efavirenz area under the concentration\u2013time curve, of the same magnitude as what has been clinically observed (22%). Efavirenz exposure depended on CYP2B6 phenotype and bodyweight. Increasing the efavirenz dose during concomitant rifampicin was predicted to be most successful in patients over 50\u2003kg regardless of CYP2B6 status.<\/jats:p><jats:p><jats:bold>CONCLUSIONS<\/jats:bold>Our findings, although based on a simulation approach using limited<jats:italic>in vitro<\/jats:italic>data, support the current recommendations for using a 50\u2003kg bodyweight cut\u2010off for efavirenz dose increment when co\u2010treating with rifampicin.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2010.03883.x","type":"journal-article","created":{"date-parts":[[2010,12,13]],"date-time":"2010-12-13T12:44:41Z","timestamp":1292244281000},"page":"536-543","source":"Crossref","is-referenced-by-count":39,"title":["<i>In silico<\/i>prediction of efavirenz and rifampicin drug\u2013drug interaction considering weight and CYP2B6 phenotype"],"prefix":"10.1111","volume":"71","author":[{"given":"Dinko","family":"Reki\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"R\u00f6shammar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jackson","family":"Mukonzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,3,11]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"1","volume-title":"Guidelines for the Use of Antiretroviral Agents in HIV\u20101\u2010Infected Adults and Adolescents","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2009"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540701383154"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1310\/M47B-R51C-X0MC-K3GW"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200109070-00011"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.049601"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.031393"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.027706"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283319908"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.112136"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004269142"},{"key":"e_1_2_7_12_2","unstructured":"Approval documentation for Sustiva\u2122 (Efavirenz) NDA no 020972.2009 Avalable athttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020972s033 021360s02lbl.pdf(last accessed December 2009)."},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-006-0127-x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100054"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241090-00004"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2005.00293.x"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000183519.45137.a6"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008315308"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000183630.27665.30"},{"key":"e_1_2_7_20_2","unstructured":"Centers for Disease Control and Prevention.Managing Drug Interactions in the Treatment of HIV\u2010Related Tuberculosis [online].2007. Available athttp:\/\/www.cdc.gov\/tb\/TB_HIV_Drugs\/default.htm(last accessed December 2009)."},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425250802691074"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2173"},{"key":"e_1_2_7_23_2","volume-title":"SimCYP User Manual Version 8","author":"Turner D","year":"2008"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21130"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/00498250310001646353"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.12.1497"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.020602"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.32.3.348"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03516.x"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-007-0412-3"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0763-z"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2003.22"},{"key":"e_1_2_7_33_2","first-page":"162","article-title":"Prediction of non\u2010specific hepatic microsomal binding from readily available physicochemical properties","volume":"38","author":"Turner DB","year":"2006","journal-title":"Drug Metab Rev"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.2174\/157016207780636588"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.107573"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.5414\/CPP40507"},{"key":"e_1_2_7_37_2","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study","volume":"18","author":"Haas DW","year":"2004","journal-title":"AIDS"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1086\/497610"},{"key":"e_1_2_7_39_2","article-title":"Physical chemical properties of efavirenz. AAPS annual meeting and exposition","author":"Rowe SM","year":"1999","journal-title":"AAPS PharmSci Supplement"},{"key":"e_1_2_7_40_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0090-9556(24)14881-7","article-title":"Nonlinear pharmacokinetics of efavirenz (DMP\u2010266), a potent HIV\u20101 reverse transcriptase inhibitor, in rats and monkeys","volume":"27","author":"Balani SK","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-006-0162-4"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2010.03883.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2010.03883.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:45:18Z","timestamp":1740768318000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2010.03883.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,11]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1111\/j.1365-2125.2010.03883.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03883.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,11]]}}}